In vivo KRAS G12D/V Degradation Mediated by CANDDY Using a Modified Proteasome Inhibitor
Imanishi, S.; Huang, L.; Itakura, S.; Ishizaka, M.; Iwasaki, Y.; Yamaguchi, T.; Miyamoto-Sato, E.
Show abstract
"Undruggable" proteins, such as RAS proteins, remain problematic despite efforts to discover inhibitors against them. KRAS mutants are prevalent in human cancers. Recently, the KRAS G12C inhibitor have been clinically approved, but inhibitors for KRAS G12D/V are still under development. Here, we described the development of a novel chemical knockdown strategy, termed CANDDY (Chemical knockdown with Affinity aNd Degradation DYnamics). This strategy involves a CANDDY tag modified from a proteasome inhibitor inducing direct proteasomal degradation. We constructed TUS-007 as a multispecific small molecule tethered from a KRAS interactor and CANDDY tag to target KRAS G12D/V. We confirmed that the degradation by TUS-007 was independent of target ubiquitination. This allows to solve a laborious design of matchmaker in the current ubiquitination-dependent proteolysis technology. And TUS-007 successfully suppressed tumors due to in vivo degradation of KRAS G12D/V. The CANDDY technology could represent a simple and rational strategy to degrade currently "undruggable" proteins.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Development of an orally bioavailable mSWI/SNF ATPase degrader and acquired mechanisms of resistance in prostate cancer 94%
- NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer 94%
- Inhibition of tumor growth by a novel engineered chimeric toxin that cleaves activated mutant and wild-type RAS 94%
Similar papers in this journal
- Enhancing CDK4/6 inhibitor therapy for medulloblastoma using nanoparticle delivery and scRNA-seq-guided combination with sapanisertib 94%
- Therapeutic targeting of SLC6A8 creatine transporter inhibits KRAS mutant and wildtype colon cancer and modulates human creatine levels 94%
- CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon restoration of RB function in malignant peripheral nerve sheath tumors 93%
Similar papers in this journal
- Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity 95%
- Prolonging lung cancer response to EGFR inhibition by targeting the selective advantage of resistant cells 94%
- Inhibiting B-cell-mediated Immunosuppression to Enhance the Immunotherapy Efficacy in Hepatocellular Carcinoma 93%
Similar papers in this journal
- Combinatorial CRISPR screen reveals FYN and KDM4 as targets for synergistic drug combination for treating triple negative breast cancer 95%
- A novel triptolide analog downregulates NF-κB and induces mitochondrial apoptosis pathways in human pancreatic cancer 94%
- The Development of a Novel Nanobody Therapeutic for SARS-CoV-2 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.